Overview

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Status:
Completed
Trial end date:
2016-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Famotidine
Interferon alpha-2
Interferon-alpha
Interferons
Ustekinumab